Peer Exchange

A discussion on the management of cold agglutinin disease, and the impact of emerging therapies in the pipeline on payer and clinician considerations.

A panel of experts highlight the burden of Alzheimer’s disease and current unmet needs related to diagnosis and treatment, discuss clinical and payer considerations for the diagnosis and management of AD, and generate discussion around future directions in the diagnosis and treatment.

Neil Minkoff, MD; Nihar R. Desai, MD, MPH; Jeffrey Turner, MD; and Om P. Ganda, MD, explore opportunities for improving population health outcomes in cardiorenal metabolic syndrome, including clinical and payer considerations of emerging diabetes treatments.

Neil Minkoff, MD; Ian Frank, MD; Ryan Bitton, PharmD, MBA; Jeffrey Crowley, MPH; and Carl Schmid, MBA explore the current landscape of HIV prevention with PrEP and discuss overcoming barriers to its use.

Dennis P. Scanlon, PhD; Emma Ciafaloni, MD; Maria Lopes, MD, MS; Kevin U. Stephens, Sr, JD, MD; and Mary Schroth, MD, FAAP, FCCP provide an overview of the disease burden in spinal muscular atrophy and give insight into clinical and payor perspectives on screening and diagnosis, current treatment options, and new disease-modifying therapies in SMA.

Bruce Feinberg, DO; Kathy Oubre, Michael Reff, RPh, MBA; Jamile M. Shammo, MD; and Ruben Mesa, MD, discuss the incorporation of quality care programs for improved disease management and patient care for MPNs.

A panel of experts discuss existing treatment options for relapsed/refractory multiple myeloma and provide practical considerations for regimen selection and emerging treatment options.

Key opinion leaders discuss the differences between acute and preventive treatment in migraine, clinical guidelines and treatment selections, and options for migraine management and prevention.

A discussion on the clinical impact of chimeric antigen receptor (CAR) T-cell therapy in relapsed/refractor (R/R) non-Hodgkin lymphoma and the role of expanding CAR T administration into the community practice setting.

Optimizing the clinical and financial aspects of disease management when covering an infused drug product under the pharmacy and medical benefit.